Patient-Centered Treatment Strategies in the Management of nAMD and DME

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

Recently approved anti-VEGF agents that target additional pathways and offer innovative delivery methods with longer-lasting effects may provide advantages over older anti-VEGF agents in managing patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). In this podcast, expert faculty discuss the roles of ophthalmologists and optometrists in managing nAMD and DME in an evolving treatment landscape, from screening and diagnosis to referral and ongoing patient care.

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Faculty:

Adrienne W. Scott, MD, FASRS

Frederick M. Leader Professor of Ophthalmology
Associate Professor of Ophthalmology, Retina Division
Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure: Grant/Research Support: Genentech/Roche; Consultant: Apellis, EyePoint, Genentech/Roche, Iveric Bio, Regeneron; Honorarium: Allergan/AbbVie, Regeneron; Material Support: Optos.

Justine Cheng, MD

Assistant Professor
Department of Ophthalmology and Vision Sciences
University of Illinois College of Medicine
Chicago, IL

Disclosure: Justine Cheng, MD, has no relevant financial relationships with ineligible companies.

Hong-Uyen Hua, MD

Assistant Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute
University of Miami Health System
Miami, FL

Disclosure: Adviser: AbbVie, Alcon, Alimera Sciences/ANI Pharmaceuticals, Genentech.

Sherrol A. Reynolds, OD, FAAO, FNAP

Professor of Optometry
Nova Southeastern University
College of Optometry
Fort Lauderdale, FL

Disclosure: Honorarium: American Diabetes Association, Genentech, Regeneron, Vision Service Plan (VSP).

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

PER® mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Release Date

May 30, 2025

Expiration Date

May 30, 2026